Hetlioz

Hetlioz is a prescription medication whose active ingredient is tasimelteon. It is formulated for oral administration, though specific strength and dosage form are not publicly detailed. Classified as a melatonin receptor agonist, Hetlioz is used primarily in the European market to address circadian rhythm sleep disorders, particularly non-24-hour sleep-wake disorder.

Hetlioz is indicated for the treatment of circadian rhythm sleep disturbances, especially in individuals with non-24-hour sleep-wake disorder. It may be considered when lifestyle adjustments and non‑pharmacologic measures are insufficient.

- Management of non-24-hour sleep-wake disorder in blind or sighted patients. - Adjunct therapy for irregular sleep patterns linked to circadian misalignment. - Support for patients with delayed sleep phase disorder when other options fail. - May improve daytime alertness and nighttime sleep quality in affected individuals. - Used under physician supervision as part of a comprehensive sleep‑health plan.

Common side effects of Hetlioz are generally mild and may include:

Common: - Headache - Nausea - Fatigue or drowsiness - Dizziness - Upper respiratory tract infection - Diarrhea

Serious: - Severe allergic reaction (anaphylaxis) - Mood changes or depression - Suicidal thoughts or behavior - Significant liver enzyme elevation - Vision disturbances

Before starting Hetlioz, patients should discuss their medical history with a healthcare professional.

- Not recommended for use during pregnancy or breastfeeding unless clearly needed. - Caution in patients with hepatic impairment; liver function may need monitoring. - May exacerbate depressive symptoms; monitor mood changes. - Use with caution in individuals with a history of allergic reactions to melatonin or related compounds. - Avoid abrupt discontinuation; tapering may be advised to prevent rebound insomnia. - Ensure regular follow‑up to assess efficacy and safety.

Hetlioz can interact with other medications, affecting its efficacy or safety.

Avoid: - Strong CYP1A2 inhibitors (e.g., fluvoxamine) that may increase tasimelteon levels. - Concurrent use with other melatonin receptor agonists.

Use with caution: - CYP1A2 inducers (e.g., smoking, rifampin) which may reduce effectiveness. - Central nervous system depressants that could enhance drowsiness. - Antidepressants, especially SSRIs, due to potential mood effects. - Medications affecting hepatic metabolism, requiring liver function monitoring. - Over‑the‑counter sleep aids, to avoid additive sleep‑related side effects.